(Q37860299)

24 August 2017

1 reference

title

Pharmacokinetics and pharmacodynamics of pegfilgrastim (English)

1 reference

24 August 2017

1 reference

1 reference

Bing-Bing Yang

1

1 reference

24 August 2017

Anna Kido

series ordinal

2

1 reference

24 August 2017

publication date

1 May 2011

1 reference

Clinical Pharmacokinetics

24 August 2017

published in

1 reference

24 August 2017

volume

50

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

295-306

1 reference

https://scigraph.springernature.com/pub.10.2165/11586040-000000000-00000

24 August 2017

exact match

0 references

cites work

Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

21 January 2018

Hematopoietic cytokines

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Macrophages specifically regulate the concentration of their own growth factor in the circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Expression and dynamic modulation of the human granulocyte colony-stimulating factor receptor in immature and differentiated myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Neutrophil elastase downmodulates native G-CSFR expression and granulocyte-macrophage colony formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Role of the kidney in hormone metabolism and its implications in clinical medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Mono-N-terminal poly(ethylene glycol)-protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

PEGylation: an approach for drug delivery. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

PEGylation of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Pegylation: a novel process for modifying pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Modification of acyl-plasmin-streptokinase complex with polyethylene glycol. Reduction of sensitivity to neutralizing antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Preparation and properties of polyethylene glycol-trypsin adducts

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Lymphatic transport of proteins after subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586040-000000000-00000

Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats

21 January 2018

1 reference

12 December 2020

Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells

1 reference

12 December 2020

Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children

1 reference

12 December 2020

Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques

1 reference

12 December 2020

Dose and outcome: the hurdle of neutropenia (Review).

1 reference

12 December 2020

Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose-dense chemotherapy

1 reference

12 December 2020

Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support

1 reference

12 December 2020

Granulocyte colony-stimulating factor and its receptor

1 reference

12 December 2020

Filgrastim (r-metHuG-CSF): the first 10 years.

1 reference

12 December 2020

Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia

1 reference

12 December 2020

Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor

1 reference

12 December 2020

Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF).

1 reference

12 December 2020

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy

1 reference

12 December 2020

A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans

1 reference

12 December 2020

The Mpl ligand and platelet homeostasis

1 reference

12 December 2020

Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing

1 reference

12 December 2020

Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function

1 reference

12 December 2020

Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study

1 reference

12 December 2020

Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients

1 reference

12 December 2020

Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer.

1 reference

12 December 2020

Human preleukemia: cellular, molecular and clinical aspects

1 reference

12 December 2020

Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats

1 reference

12 December 2020

In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer

1 reference

12 December 2020

Handling of proteins in isolated and in vitro perfused proximal tubules from rabbit kidney

1 reference

12 December 2020

Effect of lyophilization on the structure and phase changes of PEGylated-bovine serum albumin

1 reference

12 December 2020

Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects

1 reference

12 December 2020

Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo

1 reference

12 December 2020

Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts

1 reference

12 December 2020

10.2165/11586040-000000000-00000

Identifiers

DOI

1 reference

24 August 2017

1 reference